4SC discovers and develops targeted therapies for autoimmune and cancer indications.
Over the last few years 4SC has established a risk-diversified and sustainable small-molecule product pipeline. These product candidates should offer considerable advantages in terms of efficacy and side-effect profile.
The most advanced products is Vidofludimus (4SC-101) for autoimmune diseases and Resminostat (4SC-201), a pan-histone-deacetylase (HDAC) inhibitor for cancer indications. Each compound is currently in several Phase II trials to provide proof-of-concept in patients. The further development of these products will also be completed in partnerships with international biotech and pharmaceutical companies. These partnerships will allow the rapid completion of market approval studies and the commercial launch of the drugs.
4SC’s objective is to become a leading discovery and development company for autoimmune disease and cancer drugs.
The company is based in Planegg-Martinsried near Munich and was founded in 1997. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.